Implementing comprehensive prevention of mother-to-child transmission and HIV prevention for South African couples: study protocol for a randomized controlled trial by unknown
TRIALS
Jones et al. Trials 2014, 15:417
http://www.trialsjournal.com/content/15/1/417STUDY PROTOCOL Open AccessImplementing comprehensive prevention of
mother-to-child transmission and HIV prevention
for South African couples: study protocol for a
randomized controlled trial
Deborah Jones1, Karl Peltzer2,3,4*, Stephen M Weiss1, Sibusiso Sifunda2, Ntabozuko Dwane2, Shandir Ramlagan2,
Ryan Cook1, Gladys Matseke2, Vincent Maduna2 and Andrew Spence1Abstract
Background: In rural South Africa, only two-thirds of HIV-positive pregnant women seeking antenatal care at
community health centers took full advantage of ‘prevention of mother-to-child transmission’ (PMTCT) services
in 2010. Studies generally support male involvement to promote PMTCT, but the nature and impact of that
involvement is unclear and untested. Additionally, stigma, disclosure and intimate partner violence pose significant
barriers to PMTCT uptake and retention in care, suggesting that male involvement may be ‘necessary, but not
sufficient’ to reduce infant HIV incidence. This study expands on a successful United States President's Emergency
Plan for AIDS Relief (PEPFAR)-supported PMTCT couples intervention pilot study conducted in the Mpumalanga
province, targeting HIV-positive pregnant women and their partners, the primary objective being to determine
whether male partner involvement plus a behavioral intervention will significantly reduce infant HIV incidence.
Methods/design: The study follows a cluster randomized controlled design enrolling two cohorts of HIV-positive
pregnant women recruited from 12 randomly assigned Community Health Centers (CHC) (six experimental, six
control). The two cohorts will consist of women attending without their male partners (n = 720) and women attending
with their male partners (n = 720 couples), in order to determine whether the influence of male participation itself,
or combined with a behavioral PMTCT intervention, can significantly reduce infant HIV infection ante-, peri- and
postnatally.
Discussion: It is our intention to significantly increase PMTCT participation from current levels (69%) in the
Mpumalanga province to between 90 and 95% through engaging women and couples in a controlled, six session
ante- and postnatal risk-reducing and PMTCT promotion intervention addressing barriers to PMTCT (such as
stigma, disclosure, intimate partner violence, communication, infant feeding practices and safer conception) that
prevent women and men from utilizing treatment opportunities available to them and their infants. Based upon
the encouraging preliminary results from our pilot study, successful CHC adoption of the program could have
major public health policy implications for containing the epidemic among the most vulnerable populations in
rural South Africa: HIV-positive pregnant women and their infants.
Trial registration: ClinicalTrials.gov NCT02085356 (registration date: 10 March 2014).
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Prevention of mother-to-child transmission of HIV
(PMTCT) strategies have dramatically reduced infant
morbidity and mortality associated with HIV, as well as
significantly improving maternal health [1]. Computer
modeling estimates indicate that 90 to 95% participation
in PMTCT strategies plus effective pharmacologic regi-
mens would reduce infant HIV incidence to the World
Health Organization’s (WHO) goal of under 5% worldwide
[2,3]. Guidelines for PMTCT have been implemented in
most HIV-affected countries [4], however, PMTCT pro-
gram failure and dropout occurs at all stages of the ante-,
peri- and postnatal process [5]. Not all pregnant women
are tested for HIV [6], not all women receive treatment [7]
and not all mothers provided with medication take it
themselves or give it to their newborns [8]. Safer infant
feeding guidelines are not always followed, not all infants
born to HIV-infected mothers are tested and treated [3]
and mothers and newborns often miss postpartum clinic
visits [9]. Globally, it is estimated that two thirds of new-
born deaths could be avoided by utilization of existing
maternal, newborn and child health policy packages such
as family planning, PMTCT, skilled birth attendance or
clean childbirth, early identification of illness, safer infant
feeding and HIV treatment through antiretroviral therapy
(ART) [10].
In South Africa, although progress has been recorded
in the implementation of PMTCT programs, these im-
provements have, for the most part, occurred in urban-
ized areas, with rural areas remaining at unacceptably
high levels of MTCT [11]. The lack of paternal support,
stigma, lack of testing or disclosure, gender iniquities
and inequalities, intimate partner violence (IPV), lack of
PMTCT information, clinic access and poor retention in
care have been identified as major challenges to PMTCT
effectiveness in South Africa’s rural areas [12-15]. The
Mpumulanga province, the location of this trial, is a pre-
dominantly rural area with one of the lowest rates of
PMTCT participation and one of the highest antenatal
clinic (ANC) HIV prevalence rates (37%) in the country.
Increasing male participation in antenatal care has
been proposed in order to enhance PMTCT uptake [16],
however, while men are traditionally the sexual and re-
productive decision-makers in South Africa, the impact
of male involvement in PMTCT remains unclear and
untested [17]. Men possess general HIV knowledge but
lack specific information regarding PMTCT [18] and
may feel unable to attend ANCs due to work schedules
[19]. Men also may regard ANC health facilities as being
‘generally unfriendly’ to them [20]. Men are perceived
as decision-makers in the home, and feel their position
is undermined if they are expected to attend a ‘women’s
clinic program’, leading them to decline to attend ANC
visits with their partners [21]. A review of studies inAfrica involving men in antenatal care concluded that
male support, as well as involvement, may be required
to increase PMTCT uptake [22].
Additionally, as many women in sub-Saharan Africa
spend a considerable time of their adult lives pregnant
[23], one of the major components of the PMTCT con-
tinuum is the provision of reproductive health choices to
enable either the prevention of unintended pregnancies,
or appropriate planning for intended future pregnancies
[24]. Factors limiting the use of family planning are simi-
lar to those preventing PMTCT uptake, such as fear of
HIV disclosure, stigma and IPV [25], including fears of
judgmental healthcare providers with negative attitudes
towards childbearing by HIV-seropositive women [26].
When women do discuss fertility plans with providers,
the extent to which safer conception methods are
included is unclear [27]. In Cape Town, whilst over 30%
of HIV-positive women wanted additional children, and
60% in Johannesburg planned to conceive in the next
year, in both regions, most had never had a conversation
with a healthcare worker on these issues [28].
The ‘Protect Your Family’ trial tests the effectiveness
of a piloted behavioral intervention to significantly
increase adherence to the PMTCT protocol among rural
HIV-positive pregnant women, simultaneously determin-
ing whether the intervention conducted both with or
without the participation of male partners will have an
additive or synergistic (or negative) impact on PMTCT
uptake. A full factorial clinic-randomized design is
utilized, in which Phase one enrolls women (all of whom
have male partners) alone to receive the intervention or
time-matched attention control condition, and Phase
two enrolls women together with their male partners,
who receive a comparable men’s intervention (or control
sessions). It is hypothesized that women receiving the
intervention will be significantly more likely to adhere to
PMTCT protocol elements and, consequently, signifi-
cantly less likely to have an infant test HIV seropositive
as compared to those women in the control condition.
Additionally, it is hypothesized that the inclusion of male
partners during the second phase of the study will fur-
ther increase adherence to the PMTCT protocol among
the experimental condition mothers.
Pilot study
A one-year pilot project enrolling 239 couples provided
the foundation for this trial. Pregnant women and their
partners from ANCs in the Mpumalanga province of
South Africa were followed from month four of preg-
nancy to three months postpartum. Project aims were to
increase male involvement in ANC to promote PMTCT
and to reduce unprotected sex during pregnancy. Men
participated in both experimental and control condi-
tions. The experimental condition included a gender-
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reduction and PMTCT promotion, and the attention-
control condition included time-matched usual antenatal
care. Although the number of women with HIV (n =76)
was too small to derive meaningful statistical compari-
sons on medication uptake and transmission of HIV to
infants, the clinical outcomes were sufficiently compel-
ling to provide guidance and direction for the develop-
ment of this trial. Medication uptake was assessed via
dried blood spot (DBS); HIV medication was detected in
75% and 92% of experimental condition mothers and in-
fants, respectively, as compared to 50% and 75% of those
in the control condition [29]. Four infants were HIV-
positive by polymerase chain reaction (PCR) at six weeks
(one experimental, three control). Additionally, experi-
mental participants were found to have decreased their
amount of unprotected sex, increased their HIV-related
knowledge and had reduced incidences of IPV at follow-
up in comparison with control participants [30]. Qualita-
tive data from both genders reflected concerns about
serostatus disclosure and communication.
Methods/designs
Study design
This study is a clinic-randomized controlled trial using a
2 × 2 × 5 comparison: Phase (women only or couples) ×
condition (experimental or control) × time (assessments
given at baseline, 32 weeks pregnant, and six weeks, six
months and 12 months postpartum). In addition to assess-
ments, participants attend three group and one individual
or couples counseling intervention (or control) sessions
prior to birth, and two individual or couples counseling
sessions postpartum. Figure 1 presents a flow diagram for
participants in this study.Figure 1 Study flow diagram for participants in the study. AntiretrovirSite selection
Prior to initiation of study recruitment, all clinics from the
Gert Sibande and Nkangala Districts in the Mpumalanga
province were reviewed in consultation with the Provincial
Department of Health. Eligible CHCs clinics met South
African criteria for PMTCT sites, including on-site daily
HIV counselling and testing (HCT), ART distribution
and cluster of differentiation 4 (CD4) testing, ante and
postnatal counseling on infant feeding, infant HIV test-
ing, two or more trained PMTCT staff and two coun-
selors and a support group for HIV-positive mothers
and pregnant women. Twelve CHCs were randomly
assigned (see below) as intervention sites or standard of
care sites, stratified by antenatal care clinic case load in
the upper 50th percentile of MTCT rates (>13%). Se-
lected CHCs were engaged through meetings with study
staff and District and Provincial Health Officials. All 12
selected CHCs agreed to participate, and were visited by
study personnel to review the objectives of the study
with CHC staff members and discuss implementation
strategies within the existing CHC framework.
Randomization
The twelve CHCs were matched in a 1:1 ratio according
to patient census and average ANC volume, and one
clinic in each pair was randomly assigned to the experi-
mental or control condition using a computer program
written by the data manager. The matched clinics were
then assigned to the opposite condition. The randomization
process was carried out by four people. The first conducted
the computer-generated randomization assignments
stratified by clinic size (selected a seed for the random
number generator, ran the program, and completed the
table of condition assignments). The second implementedal; N = Population size.
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ments to study personnel. The third activated each inter-
vention site individually, and the fourth activated each
control site individually.Blinding
Only the Human Sciences Research Council (HSRC)
study staff activating and overseeing the sites were aware
of site assignment. All assessments will be conducted
using an audio computer-assisted self-interview (ACASI)
program. As such, participants enter their data them-
selves and are blind to their assignment. Following
randomization, clinic sites were activated individually,
and clinic staff are blinded to the condition. Training for
clinic study staff was conducted by condition, and clinic
study staff conducting the study are also blind to clinic
randomization status. Finally, data analysis to evaluate
study outcomes will be blinded to the clinic’s status as
an intervention or control intervention arm.Training of study staff members
Study staff at the CHC sites underwent formal training
on the study protocol, informed consent, protection of
human subjects, recruitment, assessment and use of
ACASI technology, with an in-depth review of the
meaning of each item in the assessment instruments
presented by ACASI, presented by the University of
Miami (UM) and HSRC investigators. Experimental
condition staff attended a five-day training course that
included an intensive review of the ‘Protect Your Family’
intervention manual, the PMTCT protocol and use of
cognitive behavioral (CB) intervention strategies in the
intervention, as well as how to manage sensitive issues
(such as serostatus disclosure, IPV, gender dynamics,
sexual risk reduction and safer conception practices).
Following the training, all staff received additional super-
vision at their CHC sites on the study protocol for data
collection. In addition, experimental condition staff will
receive additional guided training and practice on the
intervention under the supervision of the intervention
coordinator who will act as leader and then co-leader of
the intervention at each experimental CHC site for the
first two cohorts. Thus, each experimental clinic staff
person is currently conducting two sequences of group
sessions and individual counseling sessions under the
supervision of the HSRC coordinator.
Control condition staff received an identical one-day
training session on the use of ACASI technology and a
four-hour orientation to the protocol to enable them to
conduct time-equivalent group sessions comprised of
childhood disease prevention and adult health hazard
videotapes (for example measles, diarrhea management
and immunizations).Participant recruitment and enrollment
The total number of study participants (n = 2,160) will be
720 women in phase one and 720 couples (n = 1440) in
phase 2; each CHC will recruit 60 women, followed by 60
couples, over 30 months. The study began recruitment in
April 2014, and all participants are expected to be enrolled
by May 2017. Figure 2 presents a timeline of anticipated
study activities, including recruitment and follow-up.
Per South African PMTCT protocol, all women
receive pre- and post-HCT and, if HIV positive, referral
for CD4 assessment and ART. Potential candidates are
referred to the study assessor by PMTCT/HCT staff
after completing initiation of ART. Those who are inter-
ested in participation are screened for eligibility, provide
written informed consent, and are enrolled in the study.
Participants are compensated between 50 and 100 South
African Rand (approximately US$5 to 10) per assess-
ment for their time and transportation, and are provided
snacks during group and individual counseling sessions.
Eligible women are HIV-seropositive pregnant women
with partners, between 8 and 24 weeks pregnant (typical
time of entry into ANC care) and aged 18 years or older.
During phase one, these women are enrolled alone. In
phase two, both women and their partners will be en-
rolled. Male partners in the couples phase will be invited
to attend by their female partners following initial contact
with the recruiter. Those agreeing to participate will be
enrolled following provision of informed consent, main-
taining confidentiality of the serostatus of both couple
members. Per the standard of care, male partners will be
encouraged, but not required, to undergo HCT. For the
purposes of this study, primary male partners are defined
as husband, current baby’s father, current male sexual
partner or trusted male friend actively involved in the
mother’s life. All couples will be screened individually and
both members will each be asked a series of three rotating
questions which will identify them as a couple.
Persons who are actively psychotic (auditory or visual
hallucinations) or intoxicated (for example under the in-
fluence of alcohol of illegal drugs) are not eligible for the
study and will be referred for treatment. Following reso-
lution of symptoms, these persons may become eligible
for the study. There are no exclusions based on literacy
as all assessments will be administered using ACASI.
The study conforms to the Helsinki Declaration con-
cerning human rights and informed consent. Ethical ap-
proval was obtained from the University of Miami, Human
Subjects Research Office, HSRO study number 20130238,
and the Human Sciences Research Council Research Ethics
Committee protocol number REC 4/21/08/13.
Intervention condition
Intervention participants receive the PMTCT standard
of care plus three prenatal weekly two-hour gender-
Figure 2 Study time line and assessment points.
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pants) group sessions followed by one individual coun-
seling session and two monthly individual (women only)
or couples counseling sessions (one prenatal, two post-
partum) led by study-trained clinic staff (see Figure 1,
study flowchart). The ‘Protect Your Family’ interven-
tion is a manual, closed, structured behavioral risk-
reduction program targeting prevention of vertical
transmission, the importance of adherence to PMTCT
and medication use, HIV testing of family members
and prevention of transmission of HIV, stigma, serosta-
tus disclosure, partner communication, IPV, safe infant
feeding, safer conception, family planning and dual
method sexual barrier use.
Group sessions
During group sessions, participants receive CB skill
training addressing the key components of each session,
for example, how cognitions relate to anticipated out-
comes and thereby predict behavioral change. Group
members are encouraged to problem solve, providing
supportive feedback and peer mentorship on session
topics. Participants’ role play communication strategies
and complete partner communication and negotiation
homework using strategies practiced in the sessions. Par-
ticipants receive a week’s supply (approximately seven)
of condoms following each session. During phase two,
session topics for men’s and women’s groups are com-
parable, but place different emphasis on gender relevant
topics, for example, women focus on PMTCT protocol
and medication adherence and men focus on HIV test-
ing, alcohol and drug use (men’s sessions do not address
topics from the perspective of having a partner with
HIV, and do not jeopardize their partner’s HIV status).
Group session one focuses on reviewing information
regarding PMTCT, protection from HIV transmission,
partner involvement and becoming familiar with com-
munication strategies for sensitive topics including HIVserostatus disclosure, mutual testing, alcohol use, stigma
and avoiding IPV. The session concludes with a relax-
ation session. Men address the above topics with a
special focus on undergoing HCT. CB skill training
heightens participant awareness of their reactions to
PMTCT and communication.
Group session two again addresses positive communi-
cation and utilizes role playing, and continues with dis-
cussion of HIV status disclosure, prevention of IPV, and
CB skills for coping with anger and arguing. The session
then addresses PMTCT, ART and male involvement
during pregnancy. Men focus on HIV testing, alcohol
and drug use and communication. CB skills are used to
address anxiety regarding HIV status disclosure.
Group session three addresses testing for HIV to
enhance treatment and prevent transmission. The dis-
cussion continues on healthcare visits as an element of
PMTCT, infant feeding and planning for delivery. Family
planning, safer conception and the use of dual methods
of contraception following birth are discussed and a role
play is conducted. Men focus on conflict resolution and
anger management, communication and reducing and/
or avoiding IPV. Participants are encouraged to share
experiences with disclosure and problem-solving, and
are guided in applying cognitive restructuring skills in
discussing safer conception negotiation, including family
planning post-partum.
Counseling sessions
Three structured one-hour sessions are led by study-
trained CHC staff and delivered to individuals or couples
in a one-on-one format. The initial antenatal session is
followed by two additional sessions that will occur at six
weeks and three months postpartum (during phase two,
the two postnatal sessions will include male partners).
Information concerns adherence to the PMTCT protocol,
such as infant feeding practices and medication and repro-
ductive decision-making, including fertility planning and
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ation to adhere to the PMTCT protocol (the necessity to
adhere to the protocol throughout the infant’s first six
months of life, or longer, as determined by the child’s
health and feeding status). Each session also addresses
reducing risk behavior related to unintended pregnancy,
acquisition of sexually transmitted infections (STI) and
prevention of STI and HIV transmission to partners and
use of dual methods of protection (consistent use of con-
doms along with another contraceptive method).
Counseling session one is held at 32 weeks gestation,
and provided to women only, regardless of study phase.
The first session is an individual session, and reviews
PMTCT, transmission and prevention of transmission
during and following pregnancy and infant feeding. This
session focuses on a personalized review of the PMTCT
protocol (adherence to medication for both mothers
and infants, infant feeding practices and postpartum
infant care visits) and emphasizes the importance of
health facility delivery and provision of HIV medication
to both mothers and infants at delivery. The session
uses motivational interviewing (MI) to address making
a plan for infant feeding, family planning and use of
antiretroviral (ARV) medication. The session then
addresses delivery, and applies MI to guide mothers to
make a plan for delivery.
Counseling sessions two and three occur at six and
12 weeks postnatally and are provided to women (phase
one) or couples (phase two). Session two content includes
a discussion of safer conception practices and family plan-
ning using dual barrier methods (counseling sessions two
and three address these topics in a manner that will not
compromise participants’ confidentiality). The session in-
cludes a review of safe infant feeding (for example the
importance of breastfeeding for infant health and avoiding
mixed feeding), the importance of infant health clinic
visits and a discussion of immunizations. MI is used to
enhance immunization uptake, use of family planning and
safe infant feeding practices. Session three reviews safer
sex and family planning and maintaining medication use
and appointments for mother and infant, while staying on
track with feeding. ‘Well baby’ visits are used as reminders
for the infant’s appointments. MI is used to enhance safer
sex and family planning.
Control condition
Control condition participants receive the PMTCT stand-
ard of care plus a time-equivalent, group-administered
video presentation on health promotion and disease pre-
vention (such as measles, diarrheal management, dysentery
and dehydration and immunizations and vaccinations) in
three group sessions, followed by one individual and two
couple or individual women’s sessions on disease preven-
tion and health promotion.Evaluations, assessments and data management
Whenever possible, clinic and biological data will be
gathered from antenatal client records and the South
African ‘Road to Health’ booklet [31], which is filled out
as part of the standard of care for all expectant and new
mothers, and contains comprehensive health informa-
tion for their infants. All female participants are asked to
provide their Road to Health booklet at each assessment.
Postpartum clinic visits, maternal ART prescription,
intrapartum ARV provision, infant HIV status, infant
ART provision, infant feeding and infant immunizations
are confirmed from the booklet. In the event that the
participant does not provide the booklet, this data will
be collected from clinic records.
All psychosocial assessments are presented using
ACASI technology to enhance disclosure of sensitive
information and reduce the impact of low literacy. All
study materials were translated into local languages
(Zulu and Sotho) prior to study onset. Assessments in-
clude both psychosocial assessments and biological and
clinic data at study entry, pre-delivery (32 weeks preg-
nant), six weeks post-delivery, and at six and 12 months
postnatal follow-up.
Primary outcomes
Primary outcomes include infant HIV serostatus and
ART adherence for mothers and infants. Infant HIV ser-
ostatus is assessed via PCR at six weeks postnatal as part
of the South African PMTCT standard of care, and the
results will be collected from the Road to Health booklet
or clinic records. A second HIV test will be administered
at 12 months as part of study participation. ART adher-
ence for mothers will be assessed by blood sampling
(DBS) pre-delivery (32 weeks gestation), and infant ad-
herence will be assessed at six weeks postnatal by DBS.
DBS will assess the presence or absence of ARV medica-
tions for mothers on lifelong and prophylaxis regimens
(tenofovir, lamivudine, efavirenz) and infants taking
short-term PMTCT ARVs (nevirapine).
Secondary outcomes
Secondary outcomes include ante- and postnatal clinic
attendance, infant feeding, HIV serostatus disclosure,
family planning knowledge, attitudes and practices, HIV
and PMTCT knowledge, IPV and communication and
male HIV testing and engagement in PMTCT. Clinic at-
tendance is collected from the antenatal card and Road
to Health booklet as well as a study appointment log,
which is provided to all participants to help keep track
of study and clinic appointments. Facilitators and clinic
staff write their initials next to appointments as they are
completed. Infant feeding is assessed using an adaptation
of the WHO feeding scale measuring breastfeeding and
replacement feeding practices used in the seven days
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using an adaptation of the Disclosure Scale assessing dis-
closure among sexual partners, friends and family mem-
bers as well as factors associated with disclosure [33].
Family planning is assessed using a survey on know-
ledge, attitudes and use of contraception and safer con-
ception practices. Knowledge items assess perception of
risk of transmission to the partner during pregnancy
as well as knowledge of the fertility cycle and ideal time
to conceive. A conjoint analysis survey is used to assess
family planning attitudes. Contraception practices items
assess whether the pregnancy was planned or unplanned,
whether a provider was consulted prior to pregnancy,
current use of family planning and intentions to engage in
family planning in the future. HIV and PMTCT know-
ledge is assessed using an adaptation of the AIDS-Related
Knowledge Test; items reflect information about HIV
transmission, reinfection with resistant virus, condom
use and PMTCT-specific knowledge [34]. IPV and com-
munication are assessed using the Conflict Tactics
Scale, assessing conflict resolution style over the current
month and previous 12 months [35]. Finally, male HIV
testing is collected from self-report, and male engage-
ment is assessed using an adapted form of the Male
Involvement Index [36].Covariates
In addition to demographic covariates (such as age and
education level), information regarding HIV stigma and
postpartum depression is collected. Stigma is assessed
using an adaptation of the Women Involved in Life
Learning from Other Women (WiLLOW) HIV/AIDS
Stigma Instrument, measuring perceived and enacted
stigma in the home, community, workplace and health-
care settings, and the AIDS-Related Stigma Scale [37].
Postpartum depression is assessed using the Edinburgh
Postnatal Depression Scale; pregnant women and new
mothers indicate the frequency of depressive symptoms
over the past seven days [38].Quality assurance and control
Intervention fidelity is continually assessed using audio
recordings of intervention sessions and interventionist
checklists that are reviewed by the intervention coordin-
ator. A subset of intervention session audio recordings
will be reviewed for fidelity by study staff. Over the
course of the study, a randomly selected sample of 10%
of the total number of sessions will be transcribed by
study staff using headphones in private rooms at the
HSRC offices and reviewed. Data quality assurance pro-
cedures, including reviewing for errors and consistency
checks, are completed monthly by the data manager.
The quality of biological data will be monitored by thesite laboratory under the accreditation standards of the
South African National Accreditation Systems.
Statistical analyses
Preliminary analyses will include descriptive statistics
(such as means, standard deviations, frequencies and per-
centages), as well as t-tests, chi-square tests, and Pearson’s
correlations of factors associated with outcomes. Potential
confounders are those observed to have moderate associa-
tions with outcome variables in preliminary tests of associ-
ation, using a conservative α of 0.20 for significance
testing. These variables will be controlled in analyses as
appropriate. Prior to analyses, appropriate variable trans-
formations will be applied to outcome variables in order
to satisfy distributional assumptions. SAS (SAS Institute,
Inc., Cary, North Carolina, United States) and SPSS
(Statistical Packages for Social Sciences, IBM Company,
Armonk, NY, USA) will be used for all analyses using a
level of 0.05 to determine statistical significance. All study
analyses will be on an intention-to-treat basis.
A series of generalized linear mixed models will be
conducted in order to test the impact of the intervention
on study outcomes, including condition status (interven-
tion versus control), time, and the interaction of time
and condition status as the fixed predictors of interest.
Random effects will be used to account for the multi-
level data structure of repeated observations within per-
sons, persons nested within cohorts and cohorts nested
within clinics. Secondary analyses will test the moderat-
ing effect of phase (women only versus couples) as well
as explore other potential moderators such as HIV-
serostatus disclosure, self-efficacy for disclosure, and
male partner serostatus. Significant moderators will be
retained in the final model. Planned comparisons will be
made between conditions or phases at each time and
between times within each condition or phase.
In order to test the relative contribution of ART adher-
ence, safe infant feeding and retention in care on infant
HIV test outcomes at 12 months, additional analyses will
be conducted using generalized linear mixed models in
which infant HIV serostatus at 12 months will be the
outcome, and ART adherence, safe infant feeding and
retention in care will be the fixed predictors of interest.
Random effects will be similar to those described above.
Sample size determination
The sample size was determined by a power analysis for
the primary outcome of infant serostatus at six weeks.
Averaged clinic data collected during and following the
pilot study indicated that approximately 13% of infants
will be seropositive at six weeks of age. Using an HIV
PCR rate of 13% in the control arm, a power analysis in-
dicated that six sites per condition (six experimental, six
control) with an unadjusted sample size of 564 infants
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cant difference between conditions assuming a reduction
to 4% in the intervention condition and intracluster
correlation coefficients of up to 0.02 (depending on the
two rates) with a two-tailed test at the 0.05 level [39].
The sample size of 720 pregnant women per phase was
based on our experience in the pilot study, from which
we anticipate a 16% miscarriage and infant death rate
and a 5% attrition rate over 12 months (n = 156 lost;
n = 564 retained).Discussion
Despite the availability of an effective PMTCT treatment
protocol and infant feeding guidelines designed for
PMTCT, uptake in rural South Africa remains subopti-
mal [40]. The ‘Protect your Family’ trial seeks to en-
hance uptake pre- and postpartum, with the goal of
significantly reducing current vertical transmission rates
of 13% or greater to the WHO goal of less than 5%.
While there have been behavioral interventions to pro-
mote the PMTCT process, as well as studies attempting
to illustrate the contribution of male participation
to PMTCT uptake, this trial will be the first to deter-
mine the relative effectiveness of both strategies, indi-
vidually or collectively, in promoting PMTCT uptake
in rural South Africa. Implementation of the interven-
tion by CHC personnel provides the foundation for
rapid translation and scale-up of the program. If success-
ful, the ‘Protect Your Family’ intervention will provide a
generalizable, integrated, sustainable model for clinics
with high rates of HIV and a high incidence of MTCT to
optimize PMTCT program delivery and effectiveness.
Scale-up of the program would have major health policy
implications for containing the epidemic in two of the
most vulnerable affected populations in rural South
Africa - HIV-seropositive pregnant women and their infants.Trial status
The ‘Protect your Family’ trial is underway and started
recruiting participants in April 2014. Recruitment and
follow-up are expected to be completed by August 2018.
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